Update on $MYO (-0,89%)
Yesterday evening (June 9, 2026), the SEC officially reported that Thomas F. Kirk, a director on Myomo’s board, had purchased a large number of the company’s shares on the open market.
The hard facts: He added 40,002 shares to his personal portfolio at an average price of approximately $1.27. In other words, he just pumped over $50,000 of his own money into the company.
There’s an ironclad rule on the stock market: managers or directors can sell shares for a thousand reasons (taxes, buying a house, diversification)—but they buy on the open market for only one reason:
Because they’re convinced the stock price is going to skyrocket.
This insider news was the absolute catalyst for today’s price surge. It is the ultimate proof of the leadership team’s confidence in its own pipeline and strategy.
The bullish big picture
All of this is currently falling on extremely fertile ground at Myomo, which perfectly explains your observations over the past few weeks:
Strong numbers:
They already delivered excellent Q1 results in early May, with revenue significantly beating analysts’ expectations.
Growth momentum: The core business is growing rapidly. In recent weeks, there have already been several positive analyst comments classifying the stock as an undiscovered “bargain” despite the recent rise.
New contracts:
They recently signed new distribution agreements for the U.S. market (Ottobock Care Clinics), further securing recurring revenue.
